GSK’s Promacta Adds ‘Breakthrough’ Claim On Strength Of Small NIH Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplemental approval for severe aplastic anemia, a “breakthrough” designation, was based on a single-center, open-label Phase II trial in 43 patients that was conducted by the National Heart, Lung and Blood Institute.
You may also be interested in...
Genzyme’s Lumizyme REMS Eliminated Due To Expanded Indication
FDA approves Lumizyme for all Pompe disease patients, making it unnecessary to restrict use to a specific age group; Myozyme, produced at a different scale, will remain available.
FDA Drops Restricted Access Requirement For Amgen’s Nplate And GSK’s Promacta
FDA’s decision to modify the risk program for thrombocytopenia treatments may influence CMS to drop Nplate from its list of potential National Coverage Determinations.
GSK’s Promacta And Amgen’s Nplate To Face Off In ITP Market
GlaxoSmithKline’s thrombocytopenia treatment for patients with idiopathic thrombocytopenic purpura will launch the week of Nov. 24.